Biotech targets that could see some interest today per Bloomberg after Pfizer ponied up a 62% premium for Array Bio Pharma include Biohaven (NYSE:BHVN), Seattle Genetics (NASDAQ:SGEN), Arena Pharmaceuticals (NASDAQ:ARNA), Sage Therapeutics (NASDAQ:SAGE), Sarepta Therapeutics (NASDAQ:SRPT), Neurocrine Biosciences (NASDAQ:NBIX), BioMarin (NASDAQ:BMRN), Bluebird Bio (NASDAQ:BLUE) and Blueprint Medicines (NASDAQ:BPMC).
The names in the group with premarket bids already in are showing about a 1% gain.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.